Oxford BioMedica
Oxford Biomedica plc is a British cell and gene therapy Contract Development and Manufacturing Organization (CDMO) delivering viral vector bioprocessing solutions. The company develops and manufactures lentiviral and adeno-associated virus (AAV) vectors utilized in cell and gene therapy treatments using its LentiVector platform. Main revenue drivers consist of bioprocessing manufacturing fees, cell therapy contract development retainers, and commercial licensing royalties billed to pharmaceutical clients. Oxford Biomedica serves global biopharmaceutical corporations, biotechnology developers, and clinical trial sponsors across Europe, North America, and Asia. The company holds a market-leading global position as a premier specialized CDMO for lentiviral and AAV gene therapy vectors. Headquartered in Oxford, United Kingdom, Oxford Biomedica plc is listed on the London Stock Exchange.
2 of the funds FundTelligence covers report a position in Oxford BioMedica.
- Legal name
- Oxford BioMedica PLC
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 2
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Oxford BioMedica
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.07 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)